Preoperative transforming growth factor-beta 1 (TGF-beta 1) plasma levels in operable breast cancer patients

Objectives: The aim of this project was to search for new risk prognostic markers in the early stage of breast cancer. We tested preoperative plasma transforming growth factor - beta 1 (TGF- beta 1) levels in patients with operable breast cancer. Correlation with traditional prognostic markers and with positivity/negativity sentinel lymph node was evaluated. Materials and methods: Between 2003 and 2005, 36 patients with operable breast cancer (T1-2, N0-1, M0) with positive or negative sentinel lymph nodes were evaluated for their plasma TGF-beta 1. Twenty-seven healthy individuals (9 premenopausal and 18 postmenopausal) served as controls. Patients were evaluated for the traditional prognostic markers including tumor characteristics, positivity and negativity of sentinel lymph node, TNM, tumor grade, expression of tumor markers CA 15-3 and CEA, hormonal status (pre- or postmenopausal patients, estrogen and progesteron receptor expression), ERB and p53 expression. Predictive value of TGF-beta 1 level and correlation with either of the assessed parameters was tested by one way ANOVA analysis. Results: Measurements of preoperative plasma TGF-beta 1 levels in patients with operable breast cancer were significantly higher compared with healthy individuals (median 15293 and 3983 pg/ml p < 0.0001). TGF-beta 1 level in plasma of patients with a positive sentinel lymph node was significantly higher than in patients with negative sentinel lymph nodes (high vs low, median 18,9 and 14,5 ng/ml, respectively, p = 0.05). Conclusion: The determination of TGF-beta 1 status might help to identify a high-risk population early in tumor progression, for which a more appropriate therapy should be established. In the node-negative population, the up-regulation of TGF-beta 1 might constitute an early event that promotes further progression of breast tumors.

Operable breast cancer; Transforming growth factor-beta 1 (TGF- beta1); Preoperative assessment; Sentinel lymph node; Risk factor; Prognostic marker

[1] Westlake S., Cooper N.: “Cancer incidence and mortality: trends in the United kingdom and constituent countries, 1993 to 2004”. Health Stat Q., 2008 Summer, 38, 33.

[2] Perry N., Broeders M., De Wolf C., Törnberg S., Holland R., von Karsa L.: “European guidelines for quality assurance in breast cancer screening and diagnosis. Fourth edition - summary document”. Ann. Oncol., 2008, 19, 614.

[3] Desruisseau S., Palmari J., Giusti C., Romain S., Martin P.M., Berthois Y.: “Determination of TGF-beta 1 protein level in human primary breast cancers and its relationship with survival”. Br. J. Cancer, 2006, 94, 239.

[4] Akhurst R.J., Derynck R.: “TGF-beta signaling in cancer: a double-edged sword”. Trends Cell Biol., 2001, 11, 44.

[5] Bostrom K., Zebboudj A.F., Yao Y., Lin T.S., Torres A.: “Matrix GLA protein stimulates VEGF expression through increased transforming growth factor-beta1 activity in endothelial cells”. J. Biol. Chem., 2004, 17, 52904.

[6] Derynck R., Akhurst R.J., Balmain A.: “TGF-beta signaling in tumor suppression and cancer progression”. Nat. Genet., 2001, 29, 117.

[7] Wakefield L.M., Roberts A.B.: “ TGF-beta signaling: positive and negative effects on tumorigenesis”. Curr. Opin. Genet., 2002, 12, 22.

[8] Classification of malignant tumors of the breast according to clinical stage published under the auspices of the Union Internationale contre le Cancer. J. Chir. (Paris), 1959, 78, 576.

[9] Tamaki Y., Noguchi S.: “Detecting micrometastases in sentinel lymph nodes”. Nippon Geka Gakkai Zasshi, 2003, 104, 765.

[10] Kokubo M., Mitsumori M., Ishikura S., Nagata Y., Fujishiro S., Inamoto T. et al.: “Results of breast-conserving therapy for early stage breast cancer: Kyoto University experiences”. An. J. Clin. Oncol., 2000, 23, 499.

[11] Rakha E.A., El-Sayed M.E., Lee A.H., Elston C.W., Grainge M.J., Hodi Z. et al.: “Prognostic significance of nottingham histologic grade in invasive breast carcinoma”. J. Clin. Oncol., 2008, 26, 3153.

[12] Elston C.W.: “Classification and grading of invasive breast carcinoma”. Verh. Dtsch. Ges. Pathol., 2005, 89, 35.

[13] Strnad P., Rob L., Halaska M.G., Chod J., Zuntova A., Moravcova Z.: “Radioguided occult lesion localisation in combination with detection of the sentinel lymph node in non-palpable breast cancer tumours”. Eur. J. Gynaecol. Oncol., 2006, 27, 236.

[14] Okragly A., Balwit J.M., Haak-Frendscho M.: “Transforming growth factor beta-1 (TGF-beta-1): A biological paradox”. Promega notes magazine, 1994, 47, 10.

[15] Chouaib S., Paturel C.A., Chouaib F.M., Mami A., Caignard, Blay J.Y.: “The host-tumor immune conflict: from immunosuppression to resistance and destruction”. Immunol. Today, 1997, 18, 493.

[16] Derynck R., Akhurst R.J., Balmain A.: “TGF-beta signaling in tumor suppression and cancer progression”. Nat. Genet., 2001, 29, 117.

[17] Wakefield L.M., Roberts A.B.: “TGF-β signaling: positive and negative effects on tumorigenesis”. Curr. Opin. Genet. Dev., 2002, 12, 22.

[18] Akhurst R.J.: “TGF-beta antagonists: why suppress a tumor suppressor?”. J. Clin. Invest., 2002, 109, 1533.

[19] Bonig H., Banning U., Hannen M., Kim Y.M., Verheyen J., Mauz- Korholz C., Korholz D.: “Transforming growth factor-beta (1) suppresses interleukin-15-mediated interferon-gamma production in human T lymphocytes”. Scandinavian Journal of Immunology, 1999, 50, 612.

[20] Ghellal A., Li C., Hayes M., Byrne G., Bundred N., Kumar S.: “Prognostic significance of TGF-beta 1 and TGF-beta 3 in human breast carcinoma”. Anticancer Res., 2000, 20, 4413.

[21] Zavadova E., Loercher A., Verstovsek S., Verschraegen C.F., Micksche M., Freedman R.S.: “The role of macrophages in antitumor defense of patients with ovarian cancer”. Hematol. Oncol. Clin. North Am., 1999, 13, 135.

[22] Chouaib S., Paturel C., Chouaib F., Mami A., Caignard A., Blay J.Y.: “The host-tumor immune conflict: from immunosuppression to resistance and destruction”. Immunol. Today, 1997, 18, 493.

[23] Bonig H.. Banning U., Hannen M., Kim Z.M., Verheyen J., Mauz-Korholz C., Korholz D.: “Transforming growth factor-beta (1) suppresses interleukin-15-mediated interferon-gamma production in human T lymphocytes”. Scand. J. Immunol., 1999, 50, 612.

[24] Bouchard C., Galinha A., Tartour E., Fridman W.H., Sautes C.: “A transforming growth factor beta-like immunosuppressive factor in immunoglobulin G-binding factor”. J. Exp. Med., 1995, 182, 1717.

[25] Zavadova E., Savary C.A., Templin S., Verschraegen C.F., Freedman R.S.: “Maturation of dendritic cells from ovarian cancer patients”. Cancer Chemother. Pharmacol., 2001, 48, 189.

[26] Hwu P., Freedman R.S.: “The immunotherapy of patients with ovarian cancer”. J. Immunother., 2002, 25, 189.

[27] Lenzi R., Rosenblum M., Verschraegen C., Kudelka A.P., Kavanagh J.J., Hicks M.E. et al.: “Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Mullerian carcinoma, gastrointestinal primary malignancies, and mesothelioma”. Clin. Cancer Res., 2002, 8, 3686.

[28] Melichar B., Freedman R.S.: “Immunology of the peritoneal cavity: relevance for host-tumor relation”. Int. J. Gynecol. Cancer, 2002, 12, 3.

[29] Kobie J.J., Wu R.S., Kurt R.A., Lou S., Adelman M.K., Whitesell L.J. et al.: “Transforming growth factor beta inhibits the antigenpresenting functions and antitumor activity of dendritic cell vaccines”. Cancer Res., 2003, 63, 1860.

[30] Santin A.D., Bellone S., Ravaggi A., Roman J., Smith C.V., Pecorelli S. et al.: “Increased levels of interleukin-10 and transforming growth factor-beta in the plasma and ascitic fluid of patients with advanced ovarian cancer”. Br. J. Obstet. Gynecol., 2001, 108, 804.

[31] Coban S., Yüksel O., Koçkar M.C., Köklü S., Basar O., Tutkak H., Ormeci N.: “The significance of serum transforming growth factor beta 1 in detecting of gastric and colon cancers”. Hepatogastroenterology, 2007, 54, 1472.

[32] Shariat S.F., Kattan M.W., Traxel E., Andrews B., Zhu K., Wheeler T.M., Slawin K.M.: “Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression”. Clin. Cancer Res., 2004, 10, 1992.

[33] Schneider T., Sailer M., Ansorge S., Firsching R., Reinhold D.: “Increased concentrations of transforming growth factor beta1 and beta2 in the plasma of patients with glioblastoma”. J. Neurooncol., 2006, 79, 61.

[34] Ivanovic´ V., Demajo M., Krtolica K., Krajnovic´ M., Konstantinovic´ M., Baltic´ V. et al.: “Elevated plasma TGF-beta1 levels correlate with decreased survival of metastatic breast cancer patients”. Clin. Chim. Acta, 2006, 371, 191.